USP28 and ovarian carcinoma: Flow cytometry analysis (Fig. 5C, D), colony formation assay (Fig. S7A, B), and western blot (Fig. S7C, D) yielded the similar conclusions that WT USP28 enhances ovarian cancer cells resistance to olaparib, while USP28C171A had no apparent effects.